Security & Protection Services
Compare Stocks
5 / 10Stock Comparison
GEO vs UHS vs ACHC vs HCA vs THC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
GEO vs UHS vs ACHC vs HCA vs THC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Security & Protection Services | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $2.89B | $10.64B | $2.32B | $97.29B | $16.68B |
| Revenue (TTM) | $2.73B | $17.76B | $3.37B | $75.60B | $21.45B |
| Net Income (TTM) | $273M | $1.52B | $-1.11B | $6.78B | $1.70B |
| Gross Margin | 40.4% | 67.6% | 56.2% | 41.5% | 42.8% |
| Operating Margin | 10.5% | 11.5% | 11.7% | 15.8% | 16.1% |
| Forward P/E | 17.8x | 7.3x | 16.7x | 14.4x | 10.7x |
| Total Debt | $1.73B | $5.51B | $2.65B | $50.20B | $13.17B |
| Cash & Equiv. | $69M | $138M | $133M | $1.04B | $2.88B |
GEO vs UHS vs ACHC vs HCA vs THC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| The GEO Group, Inc. (GEO) | 100 | 181.6 | +81.6% |
| Universal Health Se… (UHS) | 100 | 161.2 | +61.2% |
| Acadia Healthcare C… (ACHC) | 100 | 88.0 | -12.0% |
| HCA Healthcare, Inc. (HCA) | 100 | 407.1 | +307.1% |
| Tenet Healthcare Co… (THC) | 100 | 874.9 | +774.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GEO vs UHS vs ACHC vs HCA vs THC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GEO ranks third and is worth considering specifically for quality.
- 10.0% margin vs ACHC's -32.8%
UHS is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 9.7%, EPS growth 37.3%, 3Y rev CAGR 9.0%
- Lower volatility, beta 0.62, Low D/E 74.3%, current ratio 1.05x
- 9.7% revenue growth vs THC's 3.1%
Among these 5 stocks, ACHC doesn't own a clear edge in any measured category.
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.31, yield 0.7%
- Beta 0.31, yield 0.7%, current ratio 0.83x
- Beta 0.31 vs GEO's 1.22
- 0.7% yield, 5-year raise streak, vs UHS's 0.5%, (3 stocks pay no dividend)
THC is the #2 pick in this set and the best alternative if long-term compounding and valuation efficiency is your priority.
- 5.1% 10Y total return vs GEO's 38.6%
- PEG 0.32 vs GEO's 1.26
- Lower P/E (10.7x vs 14.4x), PEG 0.32 vs 0.68
- +27.7% vs GEO's -17.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.7% revenue growth vs THC's 3.1% | |
| Value | Lower P/E (10.7x vs 14.4x), PEG 0.32 vs 0.68 | |
| Quality / Margins | 10.0% margin vs ACHC's -32.8% | |
| Stability / Safety | Beta 0.31 vs GEO's 1.22 | |
| Dividends | 0.7% yield, 5-year raise streak, vs UHS's 0.5%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +27.7% vs GEO's -17.3% | |
| Efficiency (ROA) | 11.3% ROA vs ACHC's -18.6%, ROIC 19.9% vs 5.9% |
GEO vs UHS vs ACHC vs HCA vs THC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GEO vs UHS vs ACHC vs HCA vs THC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HCA leads in 2 of 6 categories
GEO leads 1 • UHS leads 1 • THC leads 1 • ACHC leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GEO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 27.7x GEO's $2.7B. GEO is the more profitable business, keeping 10.0% of every revenue dollar as net income compared to ACHC's -32.8%. On growth, GEO holds the edge at +16.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.7B | $17.8B | $3.4B | $75.6B | $21.5B |
| EBITDAEarnings before interest/tax | $418M | $2.7B | $588M | $15.5B | $4.3B |
| Net IncomeAfter-tax profit | $273M | $1.5B | -$1.1B | $6.8B | $1.7B |
| Free Cash FlowCash after capex | -$165M | $894M | -$215M | $7.7B | $3.3B |
| Gross MarginGross profit ÷ Revenue | +40.4% | +67.6% | +56.2% | +41.5% | +42.8% |
| Operating MarginEBIT ÷ Revenue | +10.5% | +11.5% | +11.7% | +15.8% | +16.1% |
| Net MarginNet income ÷ Revenue | +10.0% | +8.6% | -32.8% | +9.0% | +7.9% |
| FCF MarginFCF ÷ Revenue | -6.1% | +5.0% | -6.4% | +10.2% | +15.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +16.6% | +9.6% | +7.6% | +6.7% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +107.1% | +17.7% | -49.8% | +44.6% | +87.6% |
Valuation Metrics
UHS leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 7.4x trailing earnings, UHS trades at a 52% valuation discount to HCA's 15.3x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.37x vs GEO's 0.85x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.9B | $10.6B | $2.3B | $97.3B | $16.7B |
| Enterprise ValueMkt cap + debt − cash | $4.5B | $16.0B | $4.8B | $146.5B | $27.0B |
| Trailing P/EPrice ÷ TTM EPS | 11.96x | 7.36x | -2.07x | 15.33x | 12.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.81x | 7.27x | 16.75x | 14.40x | 10.65x |
| PEG RatioP/E ÷ EPS growth rate | 0.85x | 0.46x | — | 0.73x | 0.37x |
| EV / EBITDAEnterprise value multiple | 11.71x | 6.13x | 8.38x | 9.46x | 6.27x |
| Price / SalesMarket cap ÷ Revenue | 1.10x | 0.61x | 0.70x | 1.29x | 0.78x |
| Price / BookPrice ÷ Book value/share | 2.02x | 1.48x | 1.07x | — | 1.93x |
| Price / FCFMarket cap ÷ FCF | — | 12.53x | — | 12.65x | 6.59x |
Profitability & Efficiency
HCA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-41 for ACHC. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs ACHC's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +18.5% | +20.7% | -40.9% | — | +19.6% |
| ROA (TTM)Return on assets | +7.2% | +9.8% | -18.6% | +11.3% | +5.7% |
| ROICReturn on invested capital | +6.2% | +12.3% | +5.9% | +19.9% | +13.2% |
| ROCEReturn on capital employed | +7.6% | +16.0% | +7.5% | +27.0% | +13.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 | 7 | 7 |
| Debt / EquityFinancial leverage | 1.15x | 0.74x | 1.24x | — | 1.47x |
| Net DebtTotal debt minus cash | $1.7B | $5.4B | $2.5B | $49.2B | $10.3B |
| Cash & Equiv.Liquid assets | $69M | $138M | $133M | $1.0B | $2.9B |
| Total DebtShort + long-term debt | $1.7B | $5.5B | $2.7B | $50.2B | $13.2B |
| Interest CoverageEBIT ÷ Interest expense | 3.12x | 10.92x | -5.99x | 5.37x | 4.28x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GEO five years ago would be worth $36,327 today (with dividends reinvested), compared to $3,970 for ACHC. Over the past 12 months, THC leads with a +27.7% total return vs GEO's -17.3%. The 3-year compound annual growth rate (CAGR) favors THC at 39.8% vs ACHC's -28.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +36.6% | -22.6% | +76.2% | -7.3% | -4.5% |
| 1-Year ReturnPast 12 months | -17.3% | -7.1% | +4.0% | +23.8% | +27.7% |
| 3-Year ReturnCumulative with dividends | +163.8% | +20.4% | -63.5% | +59.6% | +173.1% |
| 5-Year ReturnCumulative with dividends | +263.3% | +10.8% | -60.3% | +111.2% | +193.3% |
| 10-Year ReturnCumulative with dividends | +38.6% | +30.3% | -57.2% | +457.9% | +511.4% |
| CAGR (3Y)Annualised 3-year return | +38.2% | +6.4% | -28.5% | +16.9% | +39.8% |
Risk & Volatility
Evenly matched — ACHC and HCA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than GEO's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACHC currently trades 83.4% from its 52-week high vs UHS's 69.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 0.62x | 0.82x | 0.31x | 0.74x |
| 52-Week HighHighest price in past year | $27.90 | $246.33 | $30.20 | $556.52 | $247.21 |
| 52-Week LowLowest price in past year | $12.51 | $152.33 | $11.43 | $330.00 | $146.60 |
| % of 52W HighCurrent price vs 52-week peak | +78.0% | +69.0% | +83.4% | +78.2% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 67.6 | 42.6 | 42.7 | 30.7 | 52.6 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 777K | 3.1M | 1.0M | 1.2M |
Analyst Outlook
HCA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: GEO as "Buy", UHS as "Hold", ACHC as "Buy", HCA as "Buy", THC as "Buy". Consensus price targets imply 36.3% upside for THC (target: $260) vs 1.6% for ACHC (target: $26). For income investors, HCA offers the higher dividend yield at 0.68% vs UHS's 0.47%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $24.50 | $226.00 | $25.59 | $527.45 | $259.50 |
| # AnalystsCovering analysts | 12 | 43 | 25 | 46 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | — | +0.7% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | 1 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | $0.80 | — | $2.94 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +3.2% | +9.1% | +2.2% | +10.3% | +8.6% |
HCA leads in 2 of 6 categories (Profitability & Efficiency, Analyst Outlook). GEO leads in 1 (Income & Cash Flow). 1 tied.
GEO vs UHS vs ACHC vs HCA vs THC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GEO or UHS or ACHC or HCA or THC a better buy right now?
For growth investors, Universal Health Services, Inc.
(UHS) is the stronger pick with 9. 7% revenue growth year-over-year, versus 3. 1% for Tenet Healthcare Corporation (THC). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate The GEO Group, Inc. (GEO) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GEO or UHS or ACHC or HCA or THC?
On trailing P/E, Universal Health Services, Inc.
(UHS) is the cheapest at 7. 4x versus HCA Healthcare, Inc. at 15. 3x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 32x versus The GEO Group, Inc. 's 1. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — GEO or UHS or ACHC or HCA or THC?
Over the past 5 years, The GEO Group, Inc.
(GEO) delivered a total return of +263. 3%, compared to -60. 3% for Acadia Healthcare Company, Inc. (ACHC). Over 10 years, the gap is even starker: THC returned +511. 4% versus ACHC's -57. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GEO or UHS or ACHC or HCA or THC?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 31β versus The GEO Group, Inc. 's 1. 22β — meaning GEO is approximately 297% more volatile than HCA relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — GEO or UHS or ACHC or HCA or THC?
By revenue growth (latest reported year), Universal Health Services, Inc.
(UHS) is pulling ahead at 9. 7% versus 3. 1% for Tenet Healthcare Corporation (THC). On earnings-per-share growth, the picture is similar: The GEO Group, Inc. grew EPS 727. 3% year-over-year, compared to -537. 4% for Acadia Healthcare Company, Inc.. Over a 3-year CAGR, UHS leads at 9. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GEO or UHS or ACHC or HCA or THC?
The GEO Group, Inc.
(GEO) is the more profitable company, earning 9. 7% net margin versus -33. 3% for Acadia Healthcare Company, Inc. — meaning it keeps 9. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus 9. 8% for GEO. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GEO or UHS or ACHC or HCA or THC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 32x versus The GEO Group, Inc. 's 1. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 17. 8x for The GEO Group, Inc. — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 36. 3% to $259. 50.
08Which pays a better dividend — GEO or UHS or ACHC or HCA or THC?
In this comparison, HCA (0.
7% yield), UHS (0. 5% yield) pay a dividend. GEO, ACHC, THC do not pay a meaningful dividend and should not be held primarily for income.
09Is GEO or UHS or ACHC or HCA or THC better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 31), 0. 7% yield, +457. 9% 10Y return). Both have compounded well over 10 years (HCA: +457. 9%, GEO: +38. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GEO and UHS and ACHC and HCA and THC?
These companies operate in different sectors (GEO (Industrials) and UHS (Healthcare) and ACHC (Healthcare) and HCA (Healthcare) and THC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: GEO is a small-cap deep-value stock; UHS is a mid-cap deep-value stock; ACHC is a small-cap quality compounder stock; HCA is a mid-cap deep-value stock; THC is a mid-cap deep-value stock. HCA pays a dividend while GEO, UHS, ACHC, THC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.